AVEO receives EMA orphan medicinal product designation for tivozanib

[News]

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced it has received orphan medicinal product designation for tivozanib (N-{2-chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-N'-(5-methyl-3-isoxazolyl) urea hydrochloride monohydrate), its oral, triple VEGF receptor inhibitor, for the treatment of renal cell carcinoma by the European Medicines Agency (EMA).

More... (http://www.news-medical.net/news/20100624/AVEO-receives-EMA-orphan-medicinal-product-designation-for-tivozanib.aspx)